This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RGLS Regulus Therapeutics (RGLS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Regulus Therapeutics Stock (NASDAQ:RGLS) Get Regulus Therapeutics alerts:Sign Up Key Stats Today's Range$8.16▼$8.1650-Day Range$7.87▼$8.3052-Week Range$2.22▼$8.35VolumeN/AAverage Volume2.68 million shsMarket Capitalization$564.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Read More Receive RGLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGLS Stock News HeadlinesNovartis (NVS) Acquires Regulus Therapeutics for $1.7 BillionJune 28, 2025 | finance.yahoo.comNovartis completes acquisition of Regulus TherapeuticsJune 25, 2025 | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 7 at 1:00 AM | Profits Run (Ad)Regulus Therapeutics Inc.June 21, 2025 | barrons.comInsider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS)June 4, 2025 | gurufocus.comRegulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 PayoutJune 4, 2025 | seekingalpha.comRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 9, 2025 | finanznachrichten.deRegulus Therapeutics Reports First Quarter 2025 Financial Results and Recent UpdatesMay 8, 2025 | prnewswire.comSee More Headlines RGLS Stock Analysis - Frequently Asked Questions How were Regulus Therapeutics' earnings last quarter? Regulus Therapeutics Inc. (NASDAQ:RGLS) released its earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.14. When did Regulus Therapeutics' stock split? Regulus Therapeutics's stock reverse split before market open on Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Regulus Therapeutics IPO? Regulus Therapeutics (RGLS) raised $50 million in an initial public offering (IPO) on Wednesday, October 3rd 2012. The company issued 4,545,454 shares at a price of $10.00-$12.00 per share. What other stocks do shareholders of Regulus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY). Company Calendar Last Earnings5/08/2025Today5/07/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RGLS's financial health is in the Green zone, according to TradeSmith. RGLS has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:RGLS CIK1505512 Webwww.regulusrx.com Phone(858) 202-6300FaxN/AEmployees30Year Founded2007Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.53% Return on Assets-53.26% Debt Debt-to-Equity RatioN/A Current Ratio16.31 Quick Ratio16.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book6.97Miscellaneous Outstanding Shares69,230,000Free Float66,222,000Market Cap$564.92 million OptionableOptionable Beta0.35 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RGLS) was last updated on 5/7/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regulus Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regulus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGLS Stock Alerts